546 completed. 546 Phase 3, 46 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 546 | Completed 546 |
| Phase 2 | 46 | Completed 46 |
Follow Hepatitis: new trials by email Literature Review of Hepatitis trials Research Report on Hepatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Short Course Steroids in Alcohol Associated Hepatitis Prednisolone 40 mg - Alcoholic Hepatitis | Phase 3 | Completed | Asian Institute of Gastroenterology, India | 151 | 2025-04-07 | 2026-09-01 |
| Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents Mevac-A vaccine, Havrix 720 Junior - HAV, Hepatitis A | Phase 3 | Completed | Chiang Mai University | 120 | 2024-04-27 | 2025-05-04 |
| Glecaprevir/Pibrentasvir for the Treatment of PTSD Glecaprevir / Pibrentasvir Pill - PTSD | Phase 2 / Phase 3 | Completed | White River Junction Veterans Affairs Medical Center | 10 | 2023-04-01 | 2024-08-29 |
| Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) Bepirovirsen, Placebo - Chronic Hepatitis B, Hepatitis B, Chronic | Phase 3 | Completed | GlaxoSmithKline | 981 | 2022-12-07 | 2026-07-08 |
| Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) Bepirovirsen, Placebo - Chronic Hepatitis B, Hepatitis B, Chronic | Phase 3 | Completed | GlaxoSmithKline | 857 | 2022-12-06 | 2026-07-08 |
| Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HCV Patient Receiving Direct Acting Anti-viral Therapy. Zinc Supplement - Hepatitis C | Phase 3 | Completed | Tanta University | 50 | 2022-08-01 | 2023-10-17 |
| Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection Peginterferon Alfacon-2, Peginterferon Alfacon-2 placebo - Chronic Hepatitis B Virus Infection | Phase 3 | Completed | Beijing Kawin Technology Share-Holding Co., Ltd. | 336 | 2021-12-28 | 2024-08-09 |
| Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) Glecaprevir/Pibrentasvir (GLE/PIB) - Hepatitis C Virus (HCV) | Phase 3 | Completed | AbbVie | 286 | 2021-08-24 | 2025-04-06 |
| Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection Lonafarnib, Ritonavir - Hepatitis D, Chronic | Phase 3 | Completed | Soroka University Medical Center | 10 | 2021-05-15 | 2026-04-30 |
| 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C Sofosbuvir 400 MG, Ravidasvir 200mg - Hepatitis C | Phase 2 / Phase 3 | Completed | Muhammad Radzi Abu Hassan | 322 | 2021-03-23 | 2025-03-13 |
| B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B HEPLISAV-B, ENGERIX-B - HIV Infection, Hepatitis B | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 638 | 2020-12-14 | 2025-07-20 |
| A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013) HBVAXPRO™ - Hepatitis B | Phase 3 | Completed | Merck Sharp & Dohme LLC | 207 | 2020-09-02 | 2022-07-27 |
| Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection SOF/VEL, SOF/VEL/VOX - Hepatitis C Virus Infection | Phase 3 | Completed | Gilead Sciences | 87 | 2020-01-03 | 2021-10-27 |
| A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B Peginterferon alfa-2b injection, TDF - Chronic Hepatitis B | Phase 3 | Completed | Xiamen Amoytop Biotech Co., Ltd. | 475 | 2019-12-04 | 2024-03-05 |
| Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis SOF/VEL - Hepatitis C Virus Infection | Phase 3 | Completed | Gilead Sciences | 37 | 2019-10-16 | 2022-04-20 |
| Intra-dermal With Topical Imiquimod Pretreatment Versus Intra-muscular Hepatitis B Vaccination in IBD Patients Intradermal hepatitis B vaccine with imiquimod, Intramuscular hepatitis B vaccine with aqueous cream - Inflammatory Bowel Diseases, Hepatitis B | Phase 2 / Phase 3 | Completed | The University of Hong Kong | 104 | 2019-08-12 | 2022-05-18 |
| A Phase III Study to Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and RBV for HCV Type I Patients TG-2349, DAG181, Ribavirin - Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic | Phase 3 | Completed | Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. | 370 | 2019-06-13 | 2021-02-04 |
| Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD) Bulevirtide - Chronic Hepatitis Delta | Phase 3 | Completed | Gilead Sciences | 150 | 2019-04-17 | 2025-08-22 |
| Utilization of Hepatitis C Positive Kidneys in Negative Recipients Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C | Phase 2 / Phase 3 | Completed | Ohio State University | 54 | 2019-03-22 | 2023-09-13 |
| Safety of Sofosbuvir in People With Advanced Kidney Failure Sofosbuvir, Daclatasvir 60 mg - Kidney Failure, Chronic, Hepatitis C | Phase 3 | Completed | Sanjay Gandhi Postgraduate Institute of Medical Sciences | 30 | 2019-03-15 | 2021-04-06 |
Showing 20 of 546. Sign in to see all of them.
Hepatitis C (231) · Hepatitis B (158) · Hepatitis C, Chronic (158) · Diphtheria (54) · Hepatitis B, Chronic (53) · Tetanus (52) · Haemophilus Infections (44) · Whooping Cough (42) · Fibrosis (34) · Poliomyelitis (34) · Virus Diseases (18) · Hepatitis A (16) · HIV Infections (15) · Liver Diseases (14)
Digestive System Diseases (541) · Liver Diseases (532) · Infections (515) · Hepatitis, Viral, Human (510) · Blood-Borne Infections (506) · Communicable Diseases (503) · Virus Diseases (503) · RNA Virus Infections (372) · Flaviviridae Infections (306) · Pathological Conditions, Signs and Symptoms (252) · Pathologic Processes (249) · Disease Attributes (227) · Chronic Disease (221) · Hepatitis, Chronic (211)
Ribavirin (157) · peginterferon alfa-2a (78) · peginterferon alfa-2b (44) · Sofosbuvir (40) · ombitasvir (31) · paritaprevir (30) · daclatasvir (29) · dasabuvir (27) · glecaprevir and pibrentasvir (27) · Tenofovir (23) · Hepatitis B Vaccines (22) · glecaprevir (21) · pibrentasvir (20) · Engerix-B (19) · sofosbuvir-velpatasvir drug combination (18)
GlaxoSmithKline (65) · Gilead Sciences (51) · Merck Sharp & Dohme LLC (50) · AbbVie (47) · Bristol-Myers Squibb (36) · Sanofi Pasteur, a Sanofi Company (25) · Hoffmann-La Roche (13) · Janssen R&D Ireland (9) · Boehringer Ingelheim (8) · Tanabe Pharma Corporation (8) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (7) · Novartis Pharmaceuticals (7) · AbbVie (prior sponsor, Abbott) (6) · Foundation for Liver Research (6) · French National Agency for Research on AIDS and Viral Hepatitis (6)
United States (154) · France (96) · Canada (92) · Germany (82) · Spain (78) · United Kingdom (78) · Australia (67) · Italy (63) · Belgium (58) · Puerto Rico (53) · Russia (51) · Poland (46) · South Korea (44) · China (38) · Japan (37)
PMID 30977945, PMID 30012435, PMID 30923816, PMID 31568620, PMID 29461687, PMID 30529905, PMID 29377566, PMID 29404492, PMID 28193518, PMID 25040192, PMID 25583164, PMID 27847279, PMID 30868245, PMID 35174470, PMID 37771546, PMID 25445400, PMID 26743093, PMID 26947564, PMID 27553375, PMID 36740893, PMID 16026887, PMID 17716936, PMID 19052126, PMID 19553649, PMID 20189674, PMID 20955704, PMID 22239511, PMID 22626609, PMID 23234725, PMID 23364953, PMID 23607593, PMID 23607594, PMID 23939953, PMID 24126097, PMID 25179493, PMID 25196718, PMID 25277773, PMID 25532501, PMID 25710287, PMID 25777337, PMID 25788199, PMID 25987775, PMID 26173631, PMID 26321288, PMID 26575258, PMID 26683763, PMID 26936417, PMID 27049487, PMID 27658343, PMID 27920566
2014 (21), 2015 (21), 2016 (9), 2004 (6), 2009 (4), 2017 (3), 2005 (2), 2008 (2), P01HL009011 (2), U01DK082843 (2), U01DK082864 (2), U01DK082871 (2), U01DK082874 (2), U01DK082944 (2), UL1TR000004 (2)